AUPH שווי כולל של נכסי החברה Aurinia Pharmaceuticals Inc

This price trend visualization of Aurinia Pharmaceuticals (AUPH) total assets on the GURU.Markets platform, with a value of 647.38, demonstrates a company utilizing an asset-light model by outsourcing drug manufacturing to Lonza plants. The business is currently focused on the market launch of Lupkynis and adapting the drug for new diagnoses. The core strategy is driven by the ambition to establish the first oral therapy for lupus nephritis as the primary standard of care.

Total assets represent the sum of equity and debt, defining the company's resource base for profit generation. By monitoring assets via ROA, an investor can track the dynamics of the asset portfolio as mathematically reconstructed through profitability, which is critically important for Aurinia Pharmaceuticals (AUPH) during the global scaling of its immunology drug sales and expansion into international markets.